Tekla Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Tekla Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-289,029	Closed	-$6.05M	–	219
2020 Q2	$6.05M	Buy	289,029 +81,474	+39%	+$1.47M	0.23%	90
2020 Q1	$2.9M	Hold	207,555	–	–	0.13%	116
2019 Q4	$4.72M	Hold	207,555	–	–	0.18%	107
2019 Q3	$2.42M	Buy	+207,555	New	+$2.58M	0.11%	128
2016 Q4	–	Sell	-45,191	Closed	-$1.71M	–	148
2016 Q3	$1.71M	Hold	45,191	–	–	0.07%	124
2016 Q2	$1.34M	Sell	45,191 -76,657	-63%	-$2.7M	0.05%	143
2016 Q1	$3.61M	Buy	121,848 +15,598	+15%	+$468K	0.15%	99
2015 Q4	$4.82M	Hold	106,250	–	–	0.17%	96
2015 Q3	$4M	Buy	+106,250	New	+$4.88M	0.14%	110

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Tekla Capital Management's RCKT Position: Q3 2020 in Review

Tekla Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q3 2020, closing a stake of 289,029 shares — an estimated $6.05M sold.

Tekla Capital Management first reported a position in RCKT in Q3 2015 and held it in 9 quarters. The position peaked at $6.05M in Q2 2020. 126 funds tracked by Wall St. Rank hold RCKT as of Q3 2020.

Tekla Capital Management reported no remaining Rocket Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Tekla Capital Management sold 289,029 Rocket Pharmaceuticals shares in Q3 2020, an estimated $6.05M.
Tekla Capital Management first reported a position in Rocket Pharmaceuticals in Q3 2015 and held it in 9 quarters.
Tekla Capital Management's Rocket Pharmaceuticals position peaked at $6.05M in Q2 2020.
126 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2020.

Based on Tekla Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.